Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frexalimab SC vs IV in Multiple Sclerosis
NCT07325292Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Jan 2026
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of frexalimab in multiple sclerosis (MS), sponsored by Sanofi. Started Jan 2026; status: recruiting.
02
Drugs
frexalimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07325292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07325292.